



Tabelecleucel for Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease: Effectiveness and Value

Thursday • November 14, 2024 • 10:00 AM – 4:00 PM EDT

Virtual Event – Zoom Webinar

[Click Here to Register](#)

Time	Activity
10:00 AM—10:20 AM	Meeting Convened and Opening Remarks Sarah K. Emond, MPP, President and CEO, ICER Steven D. Pearson, MD, MSc, Special Advisor, ICER
10:20 AM—11:00 AM	Presentation of the Clinical Evidence Grace Lin, MD, MAS, Medical Director for Health Technology Assessment, ICER Associate Professor of Medicine and Health Policy, UCSF
11:00 AM—11:40 AM	Presentation of the Economic Model Woojung Lee, PharmD, PhD, Associate Director of Health Economics and Decision Modeling, ICER Marina Richardson, PhD, MSc, Associate Director, HTA Methods and Health Economics
11:40 AM—12:00 PM	Public Comments and Discussion
12:00 PM—12:50 PM	Lunch Break
12:50 PM—1:50 PM	New England CEPAC Vote on Clinical Effectiveness and Value Moderator: Jason H. Wasfy, MD, MPhil Associate Professor, Harvard Medical School Director of Outcomes Research and Cardiologist, Massachusetts General Hospital Heart Center
1:50 PM—2:00 PM	Break
2:00 PM—3:30 PM	Policy Roundtable Moderator: Steven D. Pearson, MD, MSc, Special Advisor, ICER
3:30 PM—4:00 PM	Reflections from New England CEPAC
4:00 PM	Meeting Adjourned

Connect with ICER on our social media channels



ICER Staff and Consultants	
Foluso Agboola, MBBS, MPH , Vice President of Research, ICER	Sarah K. Emond, MPP , President and Chief Executive Officer, ICER
Grace Ham, MSc , Senior Program and Events Coordinator, ICER	Woojung Lee, PharmD, PhD , Associate Director of Health Economics and Decision Modeling, ICER
Grace Lin, MD , Medical Director for Health Technology Assessment, ICER	Avery McKenna, BS , Associate Research Lead, ICER
Steven D. Pearson, MD, MSc , Special Advisor, ICER	Becca Piltch, MPP , Program Manager, ICER
Finn Raymond, BS , Research Assistant, ICER	Marina Richardson, PhD, MSc , Associate Director, HTA Methods and Health Economics, ICER

*No conflicts of interest to disclose, defined as individual health care stock ownership in any health plan or pharmaceutical, biotechnology, or medical device manufacturers, or any health care consultant income or honoraria from health plans or manufacturers.

Participating Members of New England CEPAC	
Austin Frakt, PhD , Associate Director, Partnered Evidence-Based Policy Resource Center, VA Boston Healthcare System and Harvard TH Chan School of Public Health	George Goshua, MD, MSc , Assistant Professor of Medicine (Hematology-Oncology), Yale
Rebecca Kirch, EVP , Policy and Programs, National Patient Advocate Foundation	Stephen Kogut, PhD , Professor, University of Rhode Island
Donald Kreis, JD , Patient/Family Advocate	Julie Kueppers, FNP, PhD , Clinical VP, Alera Group
Aaron Mitchell, MD, MPH , Assistant Attending, Memorial Sloan Kettering Cancer Center	Brian P. O'Sullivan, MD , Professor of Pediatrics, Geisel School of Medicine at Dartmouth
Jo Porter, MPH , Chief Strategy Officer, NH Center for Justice and Equity	Joseph Ross, MD, MHS , Professor of Medicine and Public Health, Yale University
Jason L. Schwartz, PhD , Associate Professor of Health Policy, Yale School of Public Health	Rishi Wadhwa, MD, MPP, MPhil , Associate Professor of Medicine, Harvard Medical School
Jason Wasfy, MD, MPhil , Associate Professor, Harvard Medical School	

*No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member's household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.

Policy Roundtable Participant	Conflict of Interest
Upton Allen, O.Ont., CD, MBBS, MSc, FAAP, FRCPC, Hon FRCP (UK), FIDSA , Chief, Division of Infectious Disease, The Hospital for Sick Children; Senior Associate Scientist, Research Institute, The Hospital for Sick Children; Professor, Pediatrics, University of Toronto	No conflicts to disclose.
Joseph A. Kopec , Patient Advocate	No conflicts to disclose.
Sarah Nikiforow MD, PhD , Technical Director, Immune Effector Cell Program, Dana-Farber Cancer Institute	Dr. Sarah Nikiforow served as a PI at Dana-Farber Cancer Center for Tabelecleucel on Atara Biotherapeutics studies (CTL 201, CTL 901, CTL 302, CTL 301, CTL 205), but she did not accept any salary support or payment for serving as PI.
Melissa Pozotrigo, PharmD, BCOP , Senior Clinical Oncology Pharmacist, Oncohealth	Dr. Pozotrigo is a full-time employee at Oncohealth.
Emily Tsiao, PharmD, BCPS , Medical Policies Clinical Pharmacist, Premera Blue Cross	Dr. Tsiao is a full-time employee at Premera Blue Cross.
Douglas Worthen , Patient Advocate	No conflicts to disclose.